India’s reestablishment of a product patent regime is shifting the focus of the domestic pharmaceutical sector towards research and innovation after long confinement to the production of cheap generics through reverse engineering processes. For now, the winner is the pharmaceutical outsourcing business, which is pulling in greater investment as global drug companies strive to defend margins at a time when patents on several of their blockbuster drugs are close to running out. Foreign...
Sorry, you do not have access to this page because you are not logged in.
If you are not a subscriber or a trialist and you want to discuss how to access our work please:
Trusted Sources helps clients identify investment opportunities in emerging markets, exploit them with greater confidence and stay alert to associated risks.
Learn more about our approach, our team and our research, as well as our media appearances.
